search
Back to results

Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles

Primary Purpose

Colorectal Neoplasms

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Oral simethicone
Sponsored by
Asan Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colorectal Neoplasms

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients who are schedule to undergo colonoscopy for a suspicion of colonic neoplasia at the investigators' institution
  • Those who agree to participate in the study

Exclusion Criteria:

  • Colonoscopy for reasons other than detecting colonic neoplasia, e.g. evaluation of inflammatory bowel disease
  • Contraindications to iodinated contrast including renal insufficiency, hypersensitivity, and hyperthyroidism
  • Acute severe colonic obstruction which is likely preclude safe and successful performance of CTC
  • Patient who is suspicious for colonic perforation
  • Pregnancy
  • Phenylketonuria (contraindication to simethicone)

Sites / Locations

  • Asan Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

Intervention-Oral Simethicone

Arm Description

Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.

Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.

Outcomes

Primary Outcome Measures

Colonic bubble-related image quality
Colonic bubble-specific image quality is evaluated semi-quantitatively in terms of colonic mucosal surface obscured/covered by colonic bubbles.

Secondary Outcome Measures

Overall image quality
Overall image quality according to the CT Colonography Reporting and Data System. Rate of C0, i.e. polyps 1 cm or larger cannot be excluded due to insufficient technical quality, is assessed.
diagnostic performance
diagnostic performance of CT colonography for detecting colonic adenoma or carcinoma 6 mm or greater in diameter

Full Information

First Posted
February 7, 2013
Last Updated
March 24, 2014
Sponsor
Asan Medical Center
Collaborators
GE Healthcare
search

1. Study Identification

Unique Protocol Identification Number
NCT01790139
Brief Title
Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
Official Title
Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
February 2013 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
January 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
Collaborators
GE Healthcare

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine whether colonic bubbles associated with CT colonography performed with iohexol for fecal/fluid tagging could be reduced by adding simethicone to the standard cathartic preparation.
Detailed Description
CT colonography (CTC) is a recently developed radiological examination to find colorectal neoplasia. Fecal/fluid tagging using oral administration of contrast is an essential procedure for CTC. Iohexol, which has recently started being used as an agent for fecal/fluid tagging, has great advantages as it has much more tolerable taste and much lower rates of adverse effects such as clamping or diarrhea compared with traditionally used Gastrografin/Gastroview. However, iohexol is frequently associated with an occurrence of a lot of bubbles in the colon, which makes CTC interpretation more time-consuming and laborious. Past experience in colonoscopy field suggests that simethicone, a safety-proven highly inexpensive over-the-counter medicine, might resolve this issue. Given the fact that patient convenience is an important factor for a successful CTC and the fact that time-intensive nature of CTC interpretation is one of the major deterrents to wide spread adoption of CTC while CTC also needs to be as time efficient as possible in order to effectively serve the role of population screening for colorectal cancer, investigating the effect of simethicone to prevent the colonic bubbles on the time efficiency of CTC interpretation would be important. If simethicone can resolve the colonic bubble problem, CTC can be performed more conveniently for the patients as well as for the interpreting radiologists. This study is to determine whether colonic bubbles associated with CT colonography performed with iohexol for fecal/fluid tagging could be reduced by adding simethicone to the standard cathartic preparation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Neoplasms

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
84 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
Arm Title
Intervention-Oral Simethicone
Arm Type
Experimental
Arm Description
Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
Intervention Type
Drug
Intervention Name(s)
Oral simethicone
Other Intervention Name(s)
Simethicone manufactured by Taejoon Pharm Co., Ltd.
Intervention Description
10 mL of simethicone is administered as an agent to prevent colonic bubbles
Primary Outcome Measure Information:
Title
Colonic bubble-related image quality
Description
Colonic bubble-specific image quality is evaluated semi-quantitatively in terms of colonic mucosal surface obscured/covered by colonic bubbles.
Time Frame
within 1 month after assessment of the other primary endpoint
Secondary Outcome Measure Information:
Title
Overall image quality
Description
Overall image quality according to the CT Colonography Reporting and Data System. Rate of C0, i.e. polyps 1 cm or larger cannot be excluded due to insufficient technical quality, is assessed.
Time Frame
within 3 months after enrollment of all the patients and acquisition of CT colonography in all enrolled patients
Title
diagnostic performance
Description
diagnostic performance of CT colonography for detecting colonic adenoma or carcinoma 6 mm or greater in diameter
Time Frame
within 3 months after enrollment of all the patients and acquisition of CT colonography in all enrolled patients

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients who are schedule to undergo colonoscopy for a suspicion of colonic neoplasia at the investigators' institution Those who agree to participate in the study Exclusion Criteria: Colonoscopy for reasons other than detecting colonic neoplasia, e.g. evaluation of inflammatory bowel disease Contraindications to iodinated contrast including renal insufficiency, hypersensitivity, and hyperthyroidism Acute severe colonic obstruction which is likely preclude safe and successful performance of CTC Patient who is suspicious for colonic perforation Pregnancy Phenylketonuria (contraindication to simethicone)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seong Ho Park, MD
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles

We'll reach out to this number within 24 hrs